title: [The effect of endothelin receptor in androgen-independent prostate cancer].
abstract: OBJECTIVE
  To study the expression of ET receptor and the apoptosis after intervened with ET receptor antagonist in androgen-independent prostate cancer.
  
  
  METHODS
  PC3, an androgen-independent prostate cancer cell line, was used. The expression of ETA and ETB receptor in PC3 was measured through RT-PCR. After intervened with selective ETA and ETB receptor antagonist, the apoptosis in PC3 was studied through flow cytometry and electron microscope.
  
  
  RESULTS
  Clear signal was obtained in PC3 for ETA receptor mRNA transcript, while the signal for ETB receptor mRNA transcript was very weak. The expression of ETA receptor mRNA was obviously reduced and the apoptosis of PC3 cell was observed after intervened with selective ETA receptor antagonist. There was no change after intervened with selective ETB receptor antagonist.
  
  
  CONCLUSIONS
  ET-1 exerts its effects through the ETA receptor subtype and ETB receptor is silenced in PC3. The expression of ETA was reduced and the apoptosis was observed in PC3 when ETA receptor was blocked. It was dose-dependent.
authors.affiliation: Department of Urology, Renji Hospital, Shanghai Second Medical University, Shanghai 200001, China.
authors.forename: Juan-jie
authors.initials: JJ
authors.lastname: Bo
authors.forename: Xu-yuan
authors.initials: XY
authors.lastname: Huang
authors.forename: Jie
authors.initials: J
authors.lastname: Sun
authors.forename: Sheng-guo
authors.initials: SG
authors.lastname: Dai
authors.forename: Yi-xin
authors.initials: YX
authors.lastname: Wang
mesh_terms: D000728:Androgens / Q000502:physiology; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D019332:Endothelin-1 / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000473:pathology*; D009842:Oligopeptides / Q000008:administration & dosage; D010456:Peptides, Cyclic / Q000008:administration & dosage; D010880:Piperidines / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000503:physiopathology; D044022:Receptor, Endothelin A / Q000378:metabolism / Q000502:physiology*; D044023:Receptor, Endothelin B / Q000378:metabolism / Q000502:physiology*
chemical_list: D000728:Androgens; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D019332:Endothelin-1; D009842:Oligopeptides; D010456:Peptides, Cyclic; D010880:Piperidines; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; C086539:BQ 788; C072247:cyclo(Trp-Asp-Pro-Val-Leu)